Former President Donald Trump is curbing his support of a controversial drug pricing plan that rose concerns among pharmaceutical executives while he was in office, STAT News’ Rachel Cohrs Zhang reports. In 2020, Trump signed an executive order ensuring that Medicare didn’t pay more for physician-administered drugs than other developed countries, the author says, noting that the Biden administration ultimately rescinded the policy. “There is no push to renew the most favored nations drug pricing policy. President Trump has promised to lower drug costs for Americans, like he did in his first term,” a Trump campaign spokesperson said in an email to STAT on Friday. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- MultiPlan names Curren Katz as chief data science officer
- Johnson & Johnson announces ERLEADA provided overall survival benefit
- Johnson & Johnson (NYSE:JNJ) to Spend $2 Billion on New Manufacturing Plant
- J&J to invest more than $2B in manufacturing facility in North Carolina
- Johnson & Johnson files for FDA approval of Darzalex Faspro-based regimen